Though “a massive 24-year global effort to eradicate [polio] forever is now within striking distance of its goal, … there is still a very real danger that the entire campaign could come undone,” Jay Winsten, associate dean at the Harvard School of Public Health, and Emily Serazin, a principal in the Washington, D.C. office of the Boston Consulting Group, write in a Wall Street Journal opinion piece. The campaign to eradicate the disease faces geopolitical challenges, “[b]ut the biggest danger faced by the campaign is a dramatic funding shortfall of $945 million — almost half the amount originally budgeted for 2012-13,” they write. “The challenges faced by the polio campaign are emblematic of problems that affect worldwide efforts to conquer vaccine-preventable diseases such as measles and whooping cough,” Winsten and Serazin state and note that a Global Vaccine Action Plan was recently compiled by a huge collaborative effort and endorsed by the World Health Assembly. “With sufficient funding and political will, the massive health and economic benefits of vaccines are indeed attainable,” they conclude (7/24).
In this opinion piece in the Atlantic, Mark Harrington, co-founder and executive director of the Treatment Action Group (TAG), says that stronger leadership from the U.S. is needed in order to end the AIDS epidemic. Harrington notes that “earlier this year, [President Obama] proposed a shocking cut of $550 million to [PEPFAR], the most successful U.S.-funded global health program in history,” and highlights his absence from “the first International AIDS Conference to be held on American soil since … 1990.” He provides “a to do list the president should consider if he wants to walk the walk,” which includes “[f]ully fund[ing] PEPFAR and support[ing] its reauthorization in 2013,” “[f]ully support[ing] the Global Fund to Fight AIDS, Tuberculosis and Malaria,” “[r]eject[ing] the congressional ban on federal funding for needle exchange,” “[r]evis[ing] and revitaliz[ing] the National HIV/AIDS Strategy,” increasing funding for NIH, and “fully funding the research, prevention, care, and treatment” needed to end the epidemic (7/24).
As part of the Guardian’s “Young people’s sexual health matters” series, Doortje Braeken, senior adviser on adolescents and youth at the International Planned Parenthood Federation (IPPF), in an opinion piece reflects upon the recent London Summit on Family Planning, and says “the biggest hurdle is that many societies don’t recognize young people as sexual beings,” and “[o]ther challenges include policy, legal, economic, cultural, educational, service delivery and supply chain management,” as well as data collection. She says the community must “[d]evelop a comprehensive approach to young people’s mental and physical health and empowerment, recognize young people as sexual beings, provide comprehensive sexuality education for all …, train providers properly, and create easily accessible services.” She continues, “Perhaps it’s now time to create a comprehensive, commonly-agreed blueprint of components that are required to achieve the outcomes we all seek with regard to young people’s sexual and reproductive health, and again with components that can be phased in according to each community’s and nation’s need” (7/24).
In an opinion piece in The Hill’s “Congress Blog,” international health consultant Taufiqur Rahman argues that funding for the HIV/AIDS response is sufficient. He says countries should pay for their own first-line antiretroviral treatment, integrate programs to include HIV prevention activities and apply pressure to bring down the cost of second-line drugs. “We are not using technology and best practices sufficiently to accelerate and sustain our gains to save more lives quickly and build country systems,” Rahman states, adding, “We do not need more funds. We need to be smarter about investing existing resources of $8 billion with careful planning, economic analysis, proper prioritization, and lots of coordinated as well as collaborative efforts.” He continues, “We now need to focus on a ‘Transition Strategy’ with countries and this requires serious rethinking and refocusing. Let us have one global strategy of transition, critical investment, and country capacity building. Focus on collaboration, integration, revised national strategy and national financing to win this battle” (7/23).
Jonathan Klein, board chair of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria and co-founder and CEO of Getty Images, writes in a guest post on Forbes, “The U.S. government has long been the world’s most stalwart Global Fund supporter, and U.S. leadership continues to be the most effective tool in leveraging additional resources for the fight against AIDS, tuberculosis and malaria, particularly at a time when budgets are universally tight.” He notes that “[f]or every $1 invested by U.S. taxpayers, the Global Fund leverages at least $2 more from international donors. And that money translates directly into lifesaving prevention and treatment.” Klein says, “Continued U.S. leadership is essential to maintain these gains and reach our health goals. … With sustained strong support, policymakers in Washington can continue to be responsible … for the uptick in people living healthy, productive lives.” Noting that U.S. foreign aid accounts for less than one percent of the federal budget, he concludes, “But it reaps enormous rewards in generating global good will, boosting national security, saving lives and creating a safer, more stable world for all of us” (7/23).
RECENT RELEASE: Kaiser Family Foundation/Washington Post Poll Shows Positive News About Public Opinion And HIV
As the XIX International AIDS Conference convenes in Washington, D.C., Kaiser Family Foundation (KFF) President and CEO Drew Altman highlights positive news about public opinion and HIV from KFF’s new survey of the American people conducted with the Washington Post in his latest “Pulling It Together” column. He says that “the American people get most of the essentials about the HIV epidemic right (but not necessarily all of the details)” and highlights some of the survey’s findings. Altman also explores factors possibly contributing to the public’s understanding of the epidemic, including media coverage, personal contact with people living with HIV, and advocacy and education efforts. Though “there is a long way to go in the effort to end the epidemic here and abroad … there is a foundation of basic public knowledge and support which will serve the HIV effort well in years ahead,” he concludes (7/23).
Michael Merson, director of the Duke Global Health Institute, writes in The Hill’s “Congress Blog” that much of the progress in the fight against HIV/AIDS “has been made — and the lives of millions of people saved — because of PEPFAR, … [t]he largest ever global investment in health by the United States government.” With PEPFAR’s “aggressive new goals” — to provide antiretroviral drugs to six million people in low- and middle-income countries, “fund 4.7 million male circumcisions and provide antiretroviral therapy to 1.5 million HIV-infected pregnant women by 2013” — “[w]e need to ask: Are we setting ambitious goals that we’re not prepared to fund or meet? Are we setting up one of our country’s greatest successes for failure?” Merson asks. He notes that “PEPFAR funding has flatlined despite these new targets and is not nearly enough to maintain progress and continue reducing new HIV/AIDS cases and deaths” and that “uncertainty” surrounds the “commitment by Congress” and the outcome of the presidential election. Saying that “PEPFAR itself also needs to continue to adjust its priorities,” Merson states that “treatment, prevention, care, health system capacity and scientific research to develop an HIV vaccine require financial commitment, strong political will and investment in resources from all stakeholders. Let us not fall behind now and bring back the suffering of the past” (7/20).
Noting the successes of PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria, former President George W. Bush writes in a Washington Post opinion piece that “[a]n important byproduct of this massive effort on HIV/AIDS has been the improvement of African health systems,” which “has raised an exciting prospect: to extend the gains on AIDS to other diseases.” Bush also discusses his work with the Pink Ribbon Red Ribbon, a public-private partnership initiative spearheaded by the Bush Institute to save women from breast and cervical cancer. Over the past decade a “global effort” has saved millions of lives, he says, adding, “It would be a sad and terrible thing if the world chose this moment to lose its focus and will.” Bush concludes, “Other countries and local governments in Africa can do more in providing resources and increasing funding … [b]ut to continue the momentum in the fight against AIDS, America must continue to lead” (7/22).
Noting the International AIDS Conference is being held in the U.S. for the first time in more than 20 years, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, reflects on an event with “government leaders, philanthropists, faith leaders, entrepreneurs and entertainers at the Kennedy Center’s Eisenhower Theatre [Saturday] night to recognize what the world has achieved in turning the tide on AIDS,” in this post in the foundation’s “Impatient Optimists” blog. Gates says the event “offered a great stage to share success stories and talk about the importance of sustained HIV funding,” and concludes, “Americans can be justifiably proud of the tremendous moral leadership that the U.S. has taken in producing breakthrough innovations in the fight against HIV” (7/22).
In this post in the Huffington Post’s “Opportunity” blog, Orin Levine, executive director of the International Vaccine Access Center (IVAC), examines “some of the available facts on global health and jobs in swing states and [presents] three reasons why the presidential campaigns should pay more attention to global health than they have so far.” Levine writes, “According to the Duke Global Health Institute, in 2007, global health contributed an estimated 7,000 jobs, more than $500,000,000 in wages and salaries and had an economic impact of $1.7-2.0 billion on the North Carolina economy”; “[n]early one-half of all the funding for global health from [USAID] went to Virginia-based institutions — over $560 million in FY 2011 and 2012 alone,” which “no doubt provide jobs to hundreds of Virginians”; and “U.S. contributions to global health and policies towards regulation, research and investments that build systems in emerging market countries will have a major impact on thousands of jobs” in Pennsylvania, where “Merck, Pfizer, GlaxoSmithKline and others have major manufacturing, commercial and research presences” (7/20).